Login to Your Account

Samsung Biologics IPO to lead South Korea as global biotech player

By Carmen Ho
Staff Writer

Thursday, November 10, 2016

HONG KONG – Newly capitalized, thanks to an IPO of its contract drug manufacturing arm that surged on its first day of trading, South Korea's Samsung Group is now looking to take a larger slice of the global biotechnology market pie.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription